Abstract

Editorial

Convalescent plasma: a valid option in the treatment of COVID-19?

Genjiao Liu and Shuang Li*

Published: 25 February, 2020 | Volume 4 - Issue 1 | Pages: 001-002

In the late of 2019, there is an outbreak of novel coronavirus disease (COVID-19) in Wuhan, China. The patients appear respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans and is transmitted mostly via droplets or contact. People of all ages are susceptible to the virus. Up to the middle of February 2020, the number of infected persons in China is over 65,000. The case fatality rate was 2.38%, and elderly men with underlying diseases were at a higher risk of death [1].

Read Full Article HTML DOI: 10.29328/journal.icci.1001012 Cite this Article Read Full Article PDF

References

  1. Zhonghua L, Xing BX, Za Z. An Update on the Epidemiological Characteristics of Novel Coronavirus pneumonia (COVID-19). 2020; 41:139-144. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32057211
  2. Giuseppe M, Stefania V, Simonetta P, Giuseppina F, Liviana C, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016; 14: 152-157. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26674811
  3. Mair JJ, Saavedra CM, Baillie JK, Cleary P, Khaw FM, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211: 80-90. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25030060
  4. Van GJ, Edwards T, de LX, Semple MG, Gallian P, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016; 374: 33-42. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26735992
  5. Luczkowiak J, Lasala F, Mora-RM, Arribas JR, Delgado R. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. J Infect Dis. 2018; 218: S574-S581. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29939289
  6. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007; 357: 1450-1451. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17914053
  7. Davey RT Jr, Fernández-CE, Markowitz N, Pett S, Babiker AG, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019; 7: 951-963. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31582358
  8. Beigel JH, Aga E, Elie-TMC, Cho J, Tebas P, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31582360
  9. http://www.xinhuanet.com/english/2020-02/14/c_138783294.htm

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More